In: Neurochemical Research, 2015, vol. 40, no. 12, p. 2639-2646
|
In: Plos pathogens, 2018, vol. 14, no. 10, p. e1007335
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as a molecular prion tweezer. scPOM-bi combines the complementarity-determining regions of the neurotoxic antibody POM1 and the neuroprotective...
|
In: Acta Neuropathologica, 2014, vol. 127, no. 2, p. 299-301
|
In: The journal of biological chemistry, 2015, vol. 290, no. 39, p. 23631-23645
Although the accumulation of a misfolded and protease-resistant form of the prion protein (PrP) is a key event in Prion pathogenesis, the cellular factors involved in its folding and quality control are poorly understood. PrP is a glycosylated and disulfide-bonded protein synthesized at the endoplasmic reticulum (ER). The ER foldase ERp57 (also known as Grp58) is highly expressed in the brain...
|
In: Journal of Neurology, 2008, vol. 255, no. 1, p. 77-88
|
In: Acta Neuropathologica, 2006, vol. 111, no. 1, p. 56-59
|
In: Acta Neuropathologica, 2007, vol. 114, no. 5, p. 501-508
|
In: Analytical and Bioanalytical Chemistry, 2009, vol. 395, no. 5, p. 1395-1401
|
In: Journal of Molecular Neuroscience, 2004, vol. 23, no. 1-2, p. 3-11
|
In: European Journal of Wildlife Research, 2008, vol. 54, no. 2, p. 189-192
|